The Journal of Allergy and Clinical Immunology
Volume 120, Issue 3, Supplement , Pages S25-S85 , September 2007

Allergen immunotherapy: A practice parameter second update

References 

  1. American College of Medical Quality's policy on development and use of practice parameters for medical quality decision-making. Available at: http://www.acmq.orq/profess/PDFs/policy5.pdf. Accessed September 26, 2006.
  2. American Academy of Allergy, Asthma and Immunology , American College of Allergy, Asthma and Immunology . Allergen immunotherapy: a practice parameter. Ann Allergy Asthma Immunol. 2003;90(suppl 1):1–40
  3. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ. 1999;318:593–596
  4. Aaronson DW, Gandhi TK. Incorrect allergy injections: allergists' experiences and recommendations for prevention. J Allergy Clin Immunol. 2004;113:1117–1121III
  5. Joint Commission National Patient Safety Goals. Available at: http://www.jointcommission.org/PatientSafety/NationalPatientSafetyGoals/. Accessed December 26, 2006.
  6. Niggemann B, Jacobsen L, Dreborg S, Ferdousi HA, Halken S, Host A, et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. 2006:855-9. III
  7. Polosa R, Li Gotti F, Mangano G, et al. Effect of immunotherapy on asthma progression, BHR and sputum eosinophils in allergic rhinitis. Allergy. 2004;59:1224–1228III
  8. Polosa R, Al-Delaimy WK, Russo C, Piccillo G, Sarva M. Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective cohort study. Respir Res. 2005;6:153;III
  9. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002;109:251–256Ib
  10. Williams PB, Ahlstedt S, Barnes JH, Soderstrom L, Portnoy J. Are our impressions of allergy test performances correct?. Ann Allergy Asthma Immunol. 2003;91:26–33
  11. Sampson HA, Munoz-Furlong A, Bock SA, et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol. 2005;115:584–591
  12. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol. 2005;115(suppl 2):S483–S523
  13. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999;341:468–475Ib
  14. Des Roches A, Paradis L, Knani J, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy. 1996;51:430–433III
  15. Kao N. Terminology used for allergen immunotherapy. Ann Allergy Asthma Immunol. 2000;84:273–274
  16. Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E. Standards for practical allergen-specific immunotherapy. Allergy. 2006;61(suppl 82):1–20
  17. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Geneva: January 27-29 1997. Allergy. 1998;53(suppl):1–42
  18. Nicklas RA, Bernstein IL, Blessing-Moore J, et al. Practice parameters for allergen immunotherapy. J Allergy Clin Immunol. 1996;98:1001–1011
  19. Noon L. Prophylactic inoculation against hay fever. Lancet. 1911;1:1572–1573
  20. Freeman J. Further observations of the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet. 1911;2:814–817
  21. Freeman J. “Rush Inoculation,” with special reference to hay fever treatment. Lancet. 1930;1:744–747
  22. Ewbank PA, Murray J, Sanders K, Curran-Everett D, Dreskin S, Nelson HS. A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract. J Allergy Clin Immunol. 2003;111:155–161Ib
  23. Creticos PS, Van Metre TE, Mardiney MR, Rosenberg GL, Norman PS, Adkinson NF. Dose response of IgE and IgG antibodies during ragweed immunotherapy. J Allergy Clin Immunol. 1984;73:94–104Ib
  24. Frew AJ, Powell RJ, Corrigan CJ, Durham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;117:319–325Ib
  25. Lent AM, Harbeck R, Strand M, et al. Immunologic response to administration of standardized dog allergen extract at differing doses. J Allergy Clin Immunol. 2006;118:1249–1256
  26. Nanda A, O'Connor M, Anand M, et al. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol. 2004;114:1339–1344Ib
  27. Van Metre TE, Adkinson NF, Amodio FJ, et al. A comparative study of the effectiveness of the Rinkel method and the current standard method of immunotherapy for ragweed pollen hay fever. J Allergy Clin Immunol. 1980;66:500–513III
  28. Van Metre TE, Adkinson NF, Lichtenstein LM, et al. A controlled study of the effectiveness of the Rinkel method of immunotherapy for ragweed pollen hay fever. J Allergy Clin Immunol. 1980;65:288–297III
  29. Till SJ, Durham SR. Immunological responses to allergen immunotherapy. Clin Allergy Immunol. 2004;18:85–104
  30. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol. 2004;113:1025–1035
  31. Durham SR, Ying S, Varney VA, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol. 1996;97:1356–1365Ib
  32. Evans R, Pence H, Kaplan H, Rocklin RE. The effect of immunotherapy on humoral and cellular responses in ragweed hayfever. J Clin Invest. 1976;57:1378–1385IIa
  33. Hamid QA, Schotman E, Jacobson MR, Walker SM, Durham SR. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol. 1997;99:254–260IIb
  34. Tulic MK, Fiset PO, Christodoulopoulos P, et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol. 2004;113:235–241Ib
  35. Bellinghausen I, Metz G, Enk AH, Christmann S, Knop J, Saloga J. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol. 1997;27:1131–1139LB
  36. Blaser K, Akdis CA. Interleukin-10, T regulatory cells and specific allergy treatment. Clin Exp Allergy. 2004;34:328–331
  37. Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol. 2003;111:1255–1261LB
  38. Jutel M, Akdis M, Budak F, et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol. 2003;33:1205–1214IIb
  39. Savolainen J, Laaksonen K, Rantio-Lehtimaki A, Terho EO. Increased expression of allergen-induced in vitro interleukin-10 and interleukin-18 mRNA in peripheral blood mononuclear cells of allergic rhinitis patients after specific immunotherapy. Clin Exp Allergy. 2004;34:413–419IIa
  40. Durham SR, Varney VA, Gaga M, et al. Grass pollen immunotherapy decreases the number of mast cells in the skin. Clin Exp Allergy. 1999;29:1490–1496Ib
  41. Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy. 2006;61:151–165
  42. Bousquet J, Braquemond P, Feinberg J, Guerin B, Maasch H, Michel FB. Specific IgE response before and after rush immunotherapy with a standardized allergen or allergoid in grass pollen allergy. Ann Allergy. 1986;56:456–459LB
  43. Gleich GJ, Zimmermann EM, Henderson LL, Yunginger JW. Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. J Allergy Clin Immunol. 1982;70:261–271IIa
  44. Lichtenstein LM, Ishizaka K, Norman PS, Sobotka AK, Hill BM. IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest. 1973;52:472–482IIb
  45. Creticos P, Adkinson NF, Kagey-Sobotka A, et al. Nasal challenge with ragweed pollen in hay fever patients: effect of immunotherapy. J Clin Invest. 1985;76:2247–2253IIb
  46. Rak S, Lowhagen O, Venge P. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J Allergy Clin Immunol. 1988;82:470–480IIb
  47. Sadan N, Rhyne MB, Mellitis ED, Goldstein EO, Levy DA, Lichtenstein LM. Immunotherapy of pollinosis in children. Investigation of the immunologic basis of clinical improvement. N Engl Med. 1969;280:623–627IIa
  48. Varney VA, Hamid QA, Gaga M, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest. 1993;92:644–651IIb
  49. Ewan PW, Deighton J, Wilson AB, Lachmann PJ. Venom-specific IgG antibodies in bee and wasp allergy: lack of correlation with protection from stings. Clin Exp Allergy. 1993;23:647–660IIb
  50. Djurup R, Malling HJ. High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens. Clin Allergy. 1987;17:459–468IIb
  51. Michils A, Baldassarre S, Ledent C, Mairesse M, Gossart B, Duchateau J. Early effect of ultrarush venom immunotherapy on the IgG antibody response. Allergy. 2000;55:455–462IIb
  52. Michils A, Mairesse M, Ledent C, Gossart B, Baldassarre S, Duchateau J. Modified antigenic reactivity of anti-phospholipase A2 IgG antibodies in patients allergic to bee venom: conversion with immunotherapy and relation to subclass expression. J Allergy Clin Immunol. 1998;102:118–126IIb
  53. Wachholz PA, Soni NK, Till SJ, Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol. 2003;112:915–922Ib
  54. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998;102:558–562
  55. American Academy of Allergy, Asthma and Immunology (AAAAI) . The use of standardized allergen extracts. J Allergy Clin Immunol. 1997;99:583–586
  56. Nelson HS. The use of standardized extracts in allergen immunotherapy. J Allergy Clin Immunol. 2000;106:41–45
  57. Turkeltaub P. Allergenic extracts. II. In vivo standardization. In:  Middleton E,  Reed CE,  Ellis EF,  Adkinson NF,  Yunginger JW editor. Allergy: principles and practice. 3rd ed.. St Louis: CV Mosby; 1988;p. 388–401
  58. Lombardero M, Carreira J, Duffort O. Monoclonal antibody based radioimmunoassay for the quantitation of the main cat allergen (Fel d I or Cat-1). J Immunol Methods. 1988;108:71–76LB
  59. Ohman JL, Sundin B. Standardized allergenic extracts derived from mammals. Clin Rev Allergy. 1987;5:37–47
  60. Lockey R, Slater J, Esch E. Preparation of standardization of allergen extracts. In:  Adkinson F,  Yunginger J,  Busse W,  Bochner B,  Holgate S,  Simons E editor. Middleton's allergy: principles and practice. 6th ed.. St Louis: Mosby; 2003;p. 573–584
  61. Cabanas R, Lopez-Serrano MC, Carreira J, et al. Importance of albumin in cross-reactivity among cat, dog and horse allergens. J Investig Allergol Clin Immunol. 2000;10:71–77LB
  62. Baer H, Godfrey H, Maloney CJ, Norman PS, Lichtenstein LM. The potency and antigen E content of commercially prepared ragweed extracts. J Allergy. 1970;45:347–354IIb
  63. Baer H, Maloney CJ, Norman PS, Marsh DG. The potency and group I antigen content of six commercially prepared grass pollen extracts. J Allergy Clin Immunol. 1974;54:157–164IIb
  64. Greenert S, Bernstein IL, Michael JG. Immune responses of non-atopic individuals to prolonged immunisation with ragweed extract. Lancet. 1971;2:1121–1123IIb
  65. Modrzynski M, Zawisza E, Moverare R, et al. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Przegl Lek. 2003;60:130–132IIa
  66. Moverare R, Elfman L, Vesterinen E, Metso T, Haahtela T. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy. 2002;57:423–430IIa
  67. Leiferman KM, Gleich GJ. The cross-reactivity of IgE antibodies with pollen allergens. I. Analyses of various species of grass pollens. J Allergy Clin Immunol. 1976;58(suppl):129–139LB
  68. Fahlbusch B, Muller WD, Rudeschko O, Jager L, Cromwell O, Fiebig H. Detection and quantification of group 4 allergens in grass pollen extracts using monoclonal antibodies. Clin Exp Allergy. 1998;28:799–807LB
  69. Gonzalez RM, Cortes C, Conde J, et al. Cross-reactivity among five major pollen allergens. Ann Allergy. 1987;59:149–154LB
  70. Karl S, Rakoski J. Hyposensitization with cross-reacting pollen allergens. Z Hautkr. 1988;63(suppl 4):55–57LB
  71. Leavengood DC, Renard RL, Martin BG, Nelson HS. Cross allergenicity among grasses determined by tissue threshold changes. J Allergy Clin Immunol. 1985;76:789–794III
  72. Lowenstein H. Timothy pollen allergens. Allergy. 1980;35:188–191LB
  73. Martin BG, Mansfield LE, Nelson HS. Cross-allergenicity among the grasses. Ann Allergy. 1985;54:99–104LB
  74. van Ree R, van Leeuwen WA, Aalberse RC. How far can we simplify in vitro diagnostics for grass pollen allergy?: a study with 17 whole pollen extracts and purified natural and recombinant major allergens. J Allergy Clin Immunol. 1998;102:184–190LB
  75. Bernstein IL, Perera M, Gallagher J, Michael JG, Johansson SG. In vitro cross-allergenicity of major aeroallergenic pollens by the radioallergosorbent technique. J Allergy Clin Immunol. 1976;57:141–152LB
  76. Phillips JW, Bucholtz GA, Fernandez-Caldas E, Bukantz SC, Lockey RF. Bahia grass pollen, a significant aeroallergen: evidence for the lack of clinical cross-reactivity with timothy grass pollen. Ann Allergy. 1989;63:503–507IIa
  77. Eusebius NP, Papalia L, Suphioglu C, et al. Oligoclonal analysis of the atopic T cell response to the group 1 allergen of Cynodon dactylon (Bermuda grass) pollen: pre- and post-allergen-specific immunotherapy. Int Arch Allergy Immunol. 2002;127:234–244LB
  78. Blaher B, Suphioglu C, Knox RB, Singh MB, McCluskey J, Rolland JM. Identification of T-cell epitopes of Lol p 9, a major allergen of ryegrass (Lolium perenne) pollen. J Allergy Clin Immunol. 1996;98:124–132LB
  79. Barletta B, Afferni C, Tinghino R, Mari A, Di Felice G, Pini C. Cross-reactivity between Cupressus arizonica and Cupressus sempervirens pollen extracts. J Allergy Clin Immunol. 1996;98:797–804LB
  80. Black J. Cedar hay fever. J Allergy. 1929;1:71–73III
  81. Pham NH, Baldo BA, Bass DJ. Cypress pollen allergy. Identification of allergens and crossreactivity between divergent species. Clin Exp Allergy. 1994;24:558–565LB
  82. Yoo TJ, Spitz E, McGerity JL. Conifer pollen allergy: studies of immunogenicity and cross antigenicity of conifer pollens in rabbit and man. Ann Allergy. 1975;34:87–93III
  83. Lowenstein H. Cross reactions among pollen antigens. Allergy. 1980;35:198–200LB
  84. Weber RW. Cross-reactivity of pollen allergens. Curr Allergy Asthma Rep. 2004;4:401–408III
  85. Zetterstrom O, Fagerberg E, Wide L. An investigation of pollen extracts from different deciduous trees in patients with springtime allergy in Sweden. Acta Allergol. 1972;27:15–21III
  86. Eriksson NE, Wihl JA, Arrendal H, Strandhede SO. Tree pollen allergy. III. Cross reactions based on results from skin prick tests and the RAST in hay fever patients. A multi-centre study. Allergy. 1987;42:205–214LB
  87. Niederberger V, Pauli G, Gronlund H, et al. Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: a quantitative IgE inhibition study with sera from different populations. J Allergy Clin Immunol. 1998;102:579–591LB
  88. White JF, Bernstein DI. Key pollen allergens in North America. Ann Allergy Asthma Immunol. 2003;91:425–43692
  89. Bousquet J, Guerin B, Hewitt B, Lim S, Michel FB. Allergy in the Mediterranean area. III: cross reactivity among Oleaceae pollens. Clin Allergy. 1985;15:439–448LB
  90. Kernerman SM, McCullough J, Green J, Ownby DR. Evidence of cross-reactivity between olive, ash, privet, and Russian olive tree pollen allergens. Ann Allergy. 1992;69:493–496III
  91. Leiferman KM, Gleich GJ, Jones RT. The cross-reactivity of IgE antibodies with pollen allergens. II. Analyses of various species of ragweed and other fall weed pollens. J Allergy Clin Immunol. 1976;58(suppl):140–148LB
  92. Yunginger JW, Gleich GJ. Measurement of ragweed antigen E by double antibody radioimmunoassay. J Allergy Clin Immunol. 1972;50:326–337LB
  93. Asero R, Weber B, Mistrello G, Amato S, Madonini E, Cromwell O. Giant ragweed specific immunotherapy is not effective in a proportion of patients sensitized to short ragweed: analysis of the allergenic differences between short and giant ragweed. J Allergy Clin Immunol. 2005;116:1036–1041IIa
  94. Katial RK, Lin FL, Stafford WW, Ledoux RA, Westley CR, Weber RW. Mugwort and sage (Artemisia) pollen cross-reactivity: ELISA inhibition and immunoblot evaluation. Ann Allergy Asthma Immunol. 1997;79:340–346LB
  95. Lewis W, Vinay P, Zenger VE. Airborne and allergenic pollen of North America. Baltimore (MD): The John Hopkins University Press; 1983;
  96. Barderas R, Villalba M, Lombardero M, Rodriguez R. Identification and characterization of Che a 1 allergen from Chenopodium album pollen. Int Arch Allergy Immunol. 2002;127:47–54LB
  97. Gomez J, Mansfield LE, Frederick RW, Rael ED. Analysis of the individual allergens of Russian thistle pollen by an enzyme-linked immunoblotting technique. J Asthma. 1989;26:243–250LB
  98. Shafiee A, Yunginger JW, Gleich GJ. Isolation and characterization of Russian thistle (Salsola pestifer) pollen allergens. J Allergy Clin Immunol. 1981;67:472–481LB
  99. Weber RW, Nelson HS. Pollen allergens and their interrelationships. Clin Rev Allergy. 1985;3:291–318III
  100. Weber RW NH. Chenopod-Amaranth cross-allergenicity: evaluated by RAST inhibition. Ann Allergy 1984;52:226. LB
  101. Weber R. Cross-reactivity among Chenopod-Amaranth weeds: skin test correlation. Ann Allergy. 1987;58:287;LB
  102. Helm RM, Squillace DL, Jones RT, Brenner RJ. Shared allergenic activity in Asian (Blattella asahinai), German (Blattella germanica), American (Periplaneta americana), and Oriental (Blatta orientalis) cockroach species. Int Arch Allergy Appl Immunol. 1990;92:154–161LB
  103. Jeong KY, Lee J, Lee IY, Ree HI, Hong CS, Yong TS. Allergenicity of recombinant Bla g 7, German cockroach tropomyosin. Allergy. 2003;58:1059–1063LB
  104. Abramson MJ, Puy MR, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med. 1995;151:969–974Ia
  105. Bousquet J, Lockey R, Malling HJ, et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American Academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 1998;81:401–405
  106. Lockey RF. “ARIA”: global guidelines and new forms of allergen immunotherapy. J Allergy Clin Immunol. 2001;108:497–499
  107. Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis. Clin Ther. 2000;22:342–350Ia
  108. Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of Hymenoptera venom hypersensitivity: a meta-analysis. Clin Ther. 2000;22:351–358Ia
  109. Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of asthma: a meta-analysis of prospective, randomized, double-blind, placebo-controlled studies. Clin Ther. 2000;22:329–341Ia
  110. Portnoy JM. Immunotherapy for asthma: unfavorable studies. Ann Allergy Asthma Immunol. 2001;87(suppl 1):28–32
  111. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2003;CD001186. Ia
  112. Lowell FC, Franklin W. A double-blind study of the effectiveness and specificity of injection therapy in ragweed hay fever. N Engl J Med. 1965;273:675–679Ib
  113. Pichler CE, Helbling A, Pichler WJ. Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. Allergy. 2001;56:301–306IIb
  114. Aas K. Hyposensitization in house dust allergy asthma. A double-blind controlled study with evaluation of the effect on bronchial sensitivity to house dust. Acta Paediatr Scand. 1971;60:264–268Ib
  115. Bonno M, Fujisawa T, Iguchi K, et al. Mite-specific induction of interleukin-2 receptor on T lymphocytes from children with mite-sensitive asthma: modified immune response with immunotherapy. J Allergy Clin Immunol. 1996;97:680–688IIa
  116. Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med. 1978;299:157–161IIa
  117. Cantani A, Arcese G, Lucenti P, Gagliesi D, Bartolucci M. A three-year prospective study of specific immunotherapy to inhalant allergens: evidence of safety and efficacy in 300 children with allergic asthma. J Investig Allergol Clin Immunol. 1997;7:90–97IIa
  118. Cantani A, Micera M. Is specific immunotherapy safe and effective in children?. Eur Rev Med Pharmacol Sci. 2000;4:139–143IV
  119. Cools M, Van Bever HP, Weyler JJ, Stevens WJ. Long-term effects of specific immunotherapy, administered during childhood, in asthmatic patients allergic to either house-dust mite or to both house-dust mite and grass pollen. Allergy. 2000;55:69–73IIa
  120. Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol. 1997;99:450–453III
  121. Hedlin G, Wille S, Browaldh L, et al. Immunotherapy in children with allergic asthma: Effect on bronchial hyperreactivity and pharmacotherapy. J Allergy Clin Immunol. 1999;103:609–614Ib
  122. Johnstone DE, Dutton A. The value of hyposensitization therapy for bronchial asthma in children—a 14-year study. Pediatrics. 1968;42:793–802Ib
  123. Ohashi Y, Nakai Y, Tanaka A, et al. Serologic study of the working mechanisms of immunotherapy for children with perennial allergic rhinitis. Arch Otolaryngol Head Neck Surg. 1998;124:1337–1346III
  124. Portnoy JM. Immunotherapy for allergic diseases. Clin Rev Allergy Immunol. 2001;21:241–259
  125. Ariano R, Kroon AM, Augeri G, Canonica GW, Passalacqua G. Long-term treatment with allergoid immunotherapy with Parietaria. Clinical and immunologic effects in a randomized, controlled trial. Allergy. 1999;54:313–319Ib
  126. Bousquet J, Becker WM, Hejjaoui A, et al. Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts. J Allergy Clin Immunol. 1991;88:43–53Ib
  127. Bousquet J, Hejjaoui A, Skassa-Brociek W, et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract. J Allergy Clin Immunol. 1987;80:591–598Ib
  128. Creticos PS, Marsh DG, Proud D, et al. Responses to ragweed-pollen nasal challenge before and after immunotherapy. J Allergy Clin Immunol. 1989;84:197–205Ib
  129. Creticos PS, Reed CE, Norman PS, et al. Ragweed immunotherapy in adult asthma. N Engl J Med. 1996;334:501–506Ib
  130. Dolz I, Martinez-Cocera C, Bartolome JM, Cimarra M. A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy. 1996;51:489–500Ib
  131. Franklin W, Lowell FC. Comparison of two dosages of ragweed extract in the treatment of pollenosis. JAMA. 1967;201:951–957
  132. Ortolani C, Pastorello EA, Incorvaia C, et al. A double-blind, placebo-controlled study of immunotherapy with an alginate-conjugated extract of Parietaria judaica in patients with Parietaria hay fever. Allergy. 1994;49:13–21Ib
  133. Malling HJ, Djurup R. Diagnosis and immunotherapy of mould allergy. VII. IgG subclass response and relation to the clinical efficacy of immunotherapy with Cladosporium. Allergy. 1988;43:60–70
  134. Horst M, Hejjaoui A, Horst V, Michel FB, Bousquet J. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol. 1990;85:460–472IIa
  135. Malling HJ, Dreborg S, Weeke B. Diagnosis and immunotherapy of mould allergy. V. Clinical efficacy and side effects of immunotherapy with Cladosporium herbarum. Allergy. 1986;41:507–519Ib
  136. Malling HJ. Diagnosis and immunotherapy of mould allergy. IV. Relation between asthma symptoms, spore counts and diagnostic tests. Allergy. 1986;41:342–350IIa
  137. Karlsson R, Agrell B, Dreborg S, et al. A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. II. In vitro results. Allergy. 1986;41:141–150Ib
  138. Dreborg S, Agrell B, Foucard T, Kjellman NI, Koivikko A, Nilsson S. A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results. Allergy. 1986;41:131–140Ib
  139. Alvarez-Cuesta E, Cuesta-Herranz J, Puyana-Ruiz J, Cuesta-Herranz C, Blanco-Quiros A. Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study. J Allergy Clin Immunol. 1994;93:556–566Ib
  140. Haugaard L, Dahl R. Immunotherapy in patients allergic to cat and dog dander. I. Clinical results. Allergy. 1992;47:249–254IIa
  141. Hedlin G, Graff-Lonnevig V, Heilborn H, et al. Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol. 1991;87:955–964IIa
  142. Ohman JL, Findlay SR, Leitermann KM. Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of in vivo and in vitro responses. J Allergy Clin Immunol. 1984;74:230–239Ib
  143. Varney VA, Edwards J, Tabbah K, Brewster H, Mavroleon G, Frew AJ. Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin Exp Allergy. 1997;27:860–867Ib
  144. Maestrelli P, Zanolla L, Pozzan M, Fabbri LM. Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. J Allergy Clin Immunol. 2004;113:643–649Ib
  145. Tabar AI, Echechipia S, Garcia BE, et al. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol. 2005;116:109–118Ib
  146. Pichler CE, Marquardsen A, Sparholt S, et al. Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity. Allergy. 1997;52:274–283Ib
  147. Bousquet J, Calvayrac P, Guerin B, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment. J Allergy Clin Immunol. 1985;76:734–744Ib
  148. Bousquet J, Hejjaoui A, Clauzel AM, et al. Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy. J Allergy Clin Immunol. 1988;82:971–977IIa
  149. Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol. 1993;91:709–722Ib
  150. McHugh SM, Lavelle B, Kemeny DM, Patel S, Ewan PW. A placebo-controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG, and IgG subclasses. J Allergy Clin Immunol. 1990;86:521–531Ib
  151. Olsen OT, Larsen KR, Jacobsan L, Svendsen UG. A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy. 1997;52:853–859Ib
  152. Pauli G, Bessot JC, Bigot H, et al. Clinical and immunologic evaluation of tyrosine-adsorbed Dermatophagoides pteronyssinus extract: a double-blind placebo-controlled trial. J Allergy Clin Immunol. 1984;74:524–535Ib
  153. Wang H, Lin X, Hao C, et al. A double-blind, placebo-controlled study of house dust mite immunotherapy in Chinese asthmatic patients. Allergy. 2006;61:191–197Ib
  154. Kang BC, Johnson J, Morgan C, Chang JL. The role of immunotherapy in cockroach asthma. J Asthma. 1988;25:205–218IB
  155. Freeman TM, Hylander R, Ortiz A, Martin ME. Imported fire ant immunotherapy: effectiveness of whole body extracts. J Allergy Clin Immunol. 1992;90:210–215IIa
  156. Triplett RF. Sensitivity to the imported fire ant: successful treatment with immunotherapy. South Med J. 1973;66:477–480III
  157. Tankersley MS, Walker RL, Butler WK, Hagan LL, Napoli DC, Freeman TM. Safety and efficacy of an imported fire ant rush immunotherapy protocol with and without prophylactic treatment. J Allergy Clin Immunol. 2002;109:556–562Ib
  158. Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy. 2005;60:801–807Ib
  159. Ferrer M, Burches E, Pelaez A, et al. Double-blind, placebo-controlled study of immunotherapy with Parietaria judaica: clinical efficacy and tolerance. J Investig Allergol Clin Immunol. 2005;15:283–292Ib
  160. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol. 2005;116:608–613Ib
  161. Walker SM, Pajno GB, Lima MT, Wilson DR, Durham SR. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol. 2001;107:87–93Ib
  162. Jacobsen L, Nuchel Petersen B, Wihl JA, Lowenstein H, Ipsen H. Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6-year) follow-up. Allergy. 1997;52:914–920III
  163. Eng PA, Borer-Reinhold M, Heijnen IAFM, Gnehm HPE. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy. 2006;61:198–201IIa
  164. Eng PA, Reinhold M, Gnehm HP. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy. 2002;57:306–312IIa
  165. Jacobsen L. Preventive aspects of immunotherapy: prevention for children at risk of developing asthma. Ann Allergy Asthma Immunol. 2001;87(suppl 1):43–46IV
  166. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy. 2001;31:1392–1397IIa
  167. Purello-D'Ambrosio F, Gangemi S, Merendino RA, et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy. 2001;31:1295–1302
  168. Sampson HA. Food anaphylaxis. Br Med Bull. 2000;56:925–935
  169. Rance F. [Current childhood food allergies]. Allerg Immunol (Paris). 2000;32:366–376IIb
  170. Bannon GA, Cockrell G, Connaughton C, et al. Engineering, characterization and in vitro efficacy of the major peanut allergens for use in immunotherapy. Int Arch Allergy Immunol. 2001;124:70–72LB
  171. Nelson HS, Lahr J, Rule R, Bock A, Leung D. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol. 1997;99:744–751IIa
  172. Enrique E, Pineda F, Malek T, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol. 2005;116:1073–1079Ib
  173. Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY. Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol. 1992;90:256–262Ib
  174. Werfel T, Breuer K, Rueff F, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy. 2006;61:202–205Ib
  175. Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy. 1992;22:440–446Ib
  176. Bussmann C, Böckenhoff A, Henke H, Werfel T, Novak N. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis?. J Allergy Clin Immunol. 2006;118:1292–1298
  177. Bucher X, Pichler WJ, Dahinden CA, Helbling A. Effect of tree pollen specific, subcutaneous immunotherapy on the oral allergy syndrome to apple and hazelnut. Allergy. 2004;59:1272–1276IIa
  178. Hansen KS, Khinchi MS, Skov PS, Bindslev-Jensen C, Poulsen LK, Malling HJ. Food allergy to apple and specific immunotherapy with birch pollen. Mol Nutr Food Res. 2004;48:441–448Ib
  179. Tankersley MS, Butler KK, Butler WK, Goetz DW. Local reactions during allergen immunotherapy do not require dose adjustment. J Allergy Clin Immunol. 2000;106:840–843III
  180. Kelso JM. The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction. Ann Allergy Asthma Immunol. 2004;92:225–227III
  181. Roy SR, Sigmon JR, Olivier J, Moffitt JE, Brown DA, Marshall GD. Increased frequency of large local reactions in patients who experience systemic reactions on allergen immunotherapy. Ann Allergy Asthma Immunol. 2007;99:82–86III
  182. Lockey RF, Nicoara-Kasti GL, Theodoropoulos DS, Bukantz SC. Systemic reactions and fatalities associated with allergen immunotherapy. Ann Allergy Asthma Immunol. 2001;87(suppl 1):47–55III
  183. Malling HJ. Minimising the risks of allergen-specific injection immunotherapy. Drug Saf. 2000;23:323–332
  184. Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol. 2006;117:169–175III
  185. Ragusa FV, Passalacqua G, Gambardella R, et al. Nonfatal systemic reactions to subcutaneous immunotherapy: a 10-year experience. J Investig Allergol Clin Immunol. 1997;7:151–154III
  186. Ragusa VF, Massolo A. Non-fatal systemic reactions to subcutaneous immunotherapy: a 20-year experience comparison of two 10-year periods. Allerg Immunol (Paris). 2004;36:52–55III
  187. Moreno C, Cuesta-Herranz J, Fernandez-Tavora L, Alvarez-Cuesta E. Immunotherapy safety: a prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases. Clin Exp Allergy. 2004;34:527–531III
  188. Bernstein DI, Wanner M, Borish L, Liss GM. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol. 2004;113:1129–1136III
  189. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol. 1987;79:660–677III
  190. Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA. Survey of fatalities from skin testing and immunotherapy 1985-1989. J Allergy Clin Immunol. 1993;92:6–15III
  191. Bousquet J, Hejjaoui A, Dhivert H, Clauzel AM, Michel FB. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. Systemic reactions during the rush protocol in patients suffering from asthma. J Allergy Clin Immunol. 1989;83:797–802IIa
  192. Greenberg MA, Kaufman CR, Gonzalez GE, Rosenblatt CD, Smith LJ, Summers RJ. Late and immediate systemic-allergic reactions to inhalant allergen immunotherapy. J Allergy Clin Immunol. 1986;77:865–870
  193. Matloff SM, Bailit IW, Parks P, Madden N, Greineder DK. Systemic reactions to immunotherapy. Allergy Proc. 1993;14:347–350IV
  194. Subcutaneous immunotherapy. Allergy. 2006;61(suppl 82):5–13
  195. Javeed N, Javeed H, Javeed S, Moussa G, Wong P, Rezai F. Refractory anaphylactoid shock potentiated by beta-blockers. Catheter Cardiovasc Diagn. 1996;39:383–384
  196. Kivity S, Yarchovsky J. Relapsing anaphylaxis to bee sting in a patient treated with beta-blocker and Ca blocker. J Allergy Clin Immunol. 1990;85:669–670IV
  197. Lang DM, Alpern MB, Visintainer PF, Smith ST. Elevated risk of anaphylactoid reaction from radiographic contrast media is associated with both beta-blocker exposure and cardiovascular disorders. Arch Intern Med. 1993;153:2033–2040III
  198. Lang DM, Alpern MB, Visintainer PF, Smith ST. Increased risk for anaphylactoid reaction from contrast media in patients on beta-adrenergic blockers or with asthma. Ann Intern Med. 1991;115:270–276III
  199. Bickell WH, Dice WH. Military antishock trousers in a patient with adrenergic-resistant anaphylaxis. Ann Emerg Med. 1984;13:189–190IV
  200. Jacobs RL, Rake GW, Fournier DC, Chilton RJ, Culver WG, Beckmann CH. Potentiated anaphylaxis in patients with drug-induced beta-adrenergic blockade. J Allergy Clin Immunol. 1981;68:125–127IV
  201. Newman BR, Schultz LK. Epinephrine-resistant anaphylaxis in a patient taking propranolol hydrochloride. Ann Allergy. 1981;47:35–37IV
  202. Toogood JH. Risk of anaphylaxis in patients receiving beta-blocker drugs. J Allergy Clin Immunol. 1988;81:1–5IV
  203. Hepner MJ, Ownby DR, Anderson JA, Rowe MS, Sears-Ewald D, Brown EB. Risk of systemic reactions in patients taking beta-blocker drugs receiving allergen immunotherapy injections. J Allergy Clin Immunol. 1990;86:407–411III
  204. Muller UR, Haeberli G. Use of beta-blockers during immunotherapy for Hymenoptera venom allergy. J Allergy Clin Immunol. 2005;115:606–610III
  205. Sherman MS, Lazar EJ, Eichacker P. A bronchodilator action of glucagon. J Allergy Clin Immunol. 1988;81:908–911IV
  206. Thomas M, Crawford I. Best evidence topic report. Glucagon infusion in refractory anaphylactic shock in patients on beta-blockers. Emerg Med J. 2005;22:272–273IV
  207. Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy. 2000;30:1144–1150III
  208. Simons FE, Chan ES, Gu X, Simons KJ. Epinephrine for the out-of-hospital (first-aid) treatment of anaphylaxis in infants: is the ampule/syringe/needle method practical?. J Allergy Clin Immunol. 2001;108:1040–1044IIa
  209. Simons FE, Gu X, Johnston LM, Simons KJ. Can epinephrine inhalations be substituted for epinephrine injection in children at risk for systemic anaphylaxis?. Pediatrics. 2000;106:1040–1044Ib
  210. Simons FE, Gu X, Silver NA, Simons KJ. EpiPen Jr versus EpiPen in young children weighing 15 to 30 kg at risk for anaphylaxis. J Allergy Clin Immunol. 2002;109:171–175Ib
  211. Simons FE, Gu X, Simons KJ. Outdated EpiPen and EpiPen Jr autoinjectors: past their prime?. J Allergy Clin Immunol. 2000;105:1025–1030Ib
  212. Simons FE, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clin Immunol. 2001;108:871–873Ib
  213. Simons FE, Roberts JR, Gu X, Simons KJ. Epinephrine absorption in children with a history of anaphylaxis. J Allergy Clin Immunol. 1998;101:33–37Ib
  214. Bernstein JA. Pharmacoeconomic considerations for allergen immunotherapy. Clin Allergy Immunol. 2004;18:151–164III
  215. Practice parameters for the diagnosis and treatment of asthma. Joint Task Force on Practice Parameters, representing the American Academy of Allergy Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 1995;96(suppl):S707–S870
  216. Li JT, Pearlman DS, Nicklas RA, et al. Algorithm for the diagnosis and management of asthma: a practice parameter update: Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 1998;81:415–420
  217. Current status of allergen immunotherapy: Shortened Version of a World Health Organisation/International Union of Immunological Societies Working Group Report. Lancet. 1989;333:259–261
  218. Moffitt JE, Golden DB, Reisman RE, et al. Stinging insect hypersensitivity: a practice parameter update. J Allergy Clin Immunol. 2004;114:869–886
  219. Duplantier JE, Freeman TM, Bahna SL, Good RA, Sher MR. Successful rush immunotherapy for anaphylaxis to imported fire ants. J Allergy Clin Immunol. 1998;101:855–856IV
  220. Nguyen SA, Napoli DC. Natural history of large local and generalized cutaneous reactions to imported fire ant stings in children. Ann Allergy Asthma Immunol. 2005;94:387–390III
  221. Valentine MD, Schuberth KC, Kagey-Sobotka A, et al. The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med. 1990;323:1601–1603III
  222. Golden DB, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med. 2004;351:668–674III
  223. Golden DB, Marsh DG, Kagey-Sobotka A, et al. Epidemiology of insect venom sensitivity. JAMA. 1989;262:240–244III
  224. Golden DB. Insect sting allergy and venom immunotherapy: a model and a mystery. J Allergy Clin Immunol. 2005;115:439–448IV
  225. Golden DB, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM. Insect sting allergy with negative venom skin test responses. J Allergy Clin Immunol. 2001;107:897–901IIa
  226. Golden DB, Tracy JM, Freeman TM, Hoffman DR. Negative venom skin test results in patients with histories of systemic reaction to a sting. J Allergy Clin Immunol. 2003;112:495–498IV
  227. Reisman RE. Insect sting allergy: the dilemma of the negative skin test reactor. J Allergy Clin Immunol. 2001;107:781–782IV
  228. Arbes SJ, Cohn RD, Yin M, Muilenberg ML, Friedman W, Zeldin DC. Dog allergen (Can f 1) and cat allergen (Fel d 1) in US homes: results from the National Survey of Lead and Allergens in Housing. J Allergy Clin Immunol. 2004;114:111–117III
  229. Matsui EC, Wood RA, Rand C, Kanchanaraksa S, Swartz L, Eggleston PA. Mouse allergen exposure and mouse skin test sensitivity in suburban, middle-class children with asthma. J Allergy Clin Immunol. 2004;113:910–915III
  230. Matsui EC, Simons E, Rand C, et al. Airborne mouse allergen in the homes of inner-city children with asthma. J Allergy Clin Immunol. 2005;115:358–363III
  231. Perry T, Matsui E, Merriman B, Duong T, Eggleston P. The prevalence of rat allergen in inner-city homes and its relationship to sensitization and asthma morbidity. J Allergy Clin Immunol. 2003;112:346–352III
  232. Lin MS, Tanner E, Lynn J, Friday GA. Nonfatal systemic allergic reactions induced by skin testing and immunotherapy. Ann Allergy. 1993;71:557–562III
  233. Valyasevi MA, Maddox DE, Li JT. Systemic reactions to allergy skin tests. Ann Allergy Asthma Immunol. 1999;83:132–136III
  234. Berg TL, Johansson SG. Allergy diagnosis with the radioallergosorbent test: a comparison with the results of skin and provocation tests in an unselected group of children with asthma and hay fever. J Allergy Clin Immunol. 1974;54:209–221IIb
  235. van der Zee JS, de Groot H, van Swieten P, Jansen HM, Aalberse RC. Discrepancies between the skin test and IgE antibody assays: study of histamine release, complement activation in vitro, and occurrence of allergen-specific IgG. J Allergy Clin Immunol. 1988;82:270–281IIb
  236. Nelson HS, Oppenheimer J, Buchmeier A, Kordash TR, Freshwater LL. An assessment of the role of intradermal skin testing in the diagnosis of clinically relevant allergy to timothy grass. J Allergy Clin Immunol. 1996;97:1193–1201IIa
  237. Wood RA, Phipatanakul W, Hamilton RG, Eggleston PA. A comparison of skin prick tests, intradermal skin tests, and RASTs in the diagnosis of cat allergy. J Allergy Clin Immunol. 1999;103:773–779IIa
  238. Esch RE. Manufacturing and standardizing fungal allergen products. J Allergy Clin Immunol. 2004;113:210–215LB
  239. Vailes L, Sridhara S, Cromwell O, Weber B, Breitenbach M, Chapman M. Quantitation of the major fungal allergens, Alt a 1 and Asp f 1, in commercial allergenic products. J Allergy Clin Immunol. 2001;107:641–646LB
  240. Nelson HS, Ikle D, Buchmeier A. Studies of allergen extract stability: the effects of dilution and mixing. J Allergy Clin Immunol. 1996;98:382–388LB
  241. Salvaggio JE, Burge HA, Chapman JA. Emerging concepts in mold allergy: what is the role of immunotherapy?. J Allergy Clin Immunol. 1993;92:217–222
  242. Bertelsen A, Andersen JB, Christensen J, Ingemann L, Kristensen T, Ostergaard PA. Immunotherapy with dog and cat extracts in children. Allergy. 1989;44:330–335Ib
  243. Schou C, Lind P, Fernandez-Caldas E, Lockey RF, Lowenstein H. Identification and purification of an important cross-reactive allergen from American (Periplaneta americana) and German (Blattella germanica) cockroach. J Allergy Clin Immunol. 1990;86:935–946LB
  244. Bousquet J, Muller UR, Dreborg S, et al. Immunotherapy with Hymenoptera venoms. Position paper of the Working Group on Immunotherapy of the European Academy of Allergy and Clinical Immunology. Allergy. 1987;42:401–413
  245. Rueff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol. 2001;108:1027–1032III
  246. Kordash TR, Amend MJ, Williamson SL, Jones JK, Plunkett GA. Effect of mixing allergenic extracts containing helminthosporium, D. farinae, and cockroach with perennial ryegrass. Ann Allergy. 1993;71:240–246LB
  247. Grier TJ, LeFevre DM, Duncan EA, Esch RE. Stability of standardized grass, dust mite, cat and short ragweed allergens after mixing with mold or cockroach extracts. Ann Allergy Asthma Immunol. 2007;99:151–160LB
  248. Esch RE. Role of proteases on the stability of allergenic extracts. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 1992;85:171–179LB
  249. Anderson MC, Baer H. Antigenic and allergenic changes during storage of a pollen extract. J Allergy Clin Immunol. 1982;69:3–10LB
  250. Sridhara S, Singh BP, Arora N, Verma J, Gangal SV. A study on antigenic and allergenic changes during storage in three different biological extracts. Asian Pac J Allergy Immunol. 1992;10:33–38LB
  251. Niemeijer NR, Kauffman HF, van Hove W, Dubois AE, de Monchy JG. Effect of dilution, temperature, and preservatives on the long-term stability of standardized inhalant allergen extracts. Ann Allergy Asthma Immunol. 1996;76:535–540LB
  252. Vijay HM, Young NM, Bernstein IL. Studies on Alternaria allergens. VI. Stability of the allergen components of Alternaria tenuis extracts under a variety of storage conditions. Int Arch Allergy Appl Immunol. 1987;83:325–328LB
  253. Ayuso R, Rubio M, Herrera T, Gurbindo C, Carreira J. Stability of Lolium perenne extract. Ann Allergy. 1984;53:426–431LB
  254. Van Metre TE, Rosenberg GL, Vaswani SK, Ziegler SR, Adkinson NF. Pain and dermal reaction caused by injected glycerin in immunotherapy solutions. J Allergy Clin Immunol. 1996;97:1033–1039
  255. Lowenstein H. Domestic allergens. In:  Kerr J editors. Procedures of the XI International Congress of Allergology & Clinical Immunology. London: MacMillan; 1983;p. 545–548
  256. Lind P, Weeke B, Lowenstein H. A reference allergen preparation of the house dust mite D. pteronyssinus, produced from whole mite culture—a part of the DAS 76 study. Comparison with allergen preparations from other raw materials. Allergy. 1984;39:259–274LB
  257. Lowenstein H, Marsh DG. Antigens of Ambrosia elatior (short ragweed) pollen. I. Crossed immunoelectrophoretic analyses. J Immunol. 1981;126:943–948LB
  258. Lowenstein H, King TP, Goodfriend L, Hussain R, Roebber M, Marsh DG. Antigens of Ambrosia elatior (short ragweed) pollen. II. Immunochemical identification of known antigens by quantitative immunoelectrophoresis. J Immunol. 1981;127:637–642LB
  259. Aukrust L. Crossed radioimmunoelectrophoretic studies of distinct allergens in two extracts of Cladosporium herbarum. Int Arch Allergy Appl Immunol. 1979;58:375–390LB
  260. Bodtger U, Poulsen LK, Jacobi HH, Malling HJ. The safety and efficacy of subcutaneous birch pollen immunotherapy—a one-year, randomised, double-blind, placebo-controlled study. Allergy. 2002;57:297–305Ib
  261. Pence HL, Mitchell DQ, Greely RL, Updegraff BR, Selfridge HA. Immunotherapy for mountain cedar pollinosis. A double-blind controlled study. J Allergy Clin Immunol. 1976;58:39–50Ib
  262. Tipton WR, Nelson HS. Experience with daily immunotherapy in 59 adult allergic patients. J Allergy Clin Immunol. 1982;69:194–199IIa
  263. Cox L. Accelerated immunotherapy schedules: review of efficacy and safety. Ann Allergy Asthma Immunol. 2006;97:126–140202
  264. Mauro M, Russello M, Alesina R, et al. Safety and pharmacoeconomics of a cluster administration of mite immunotherapy compared to the traditional one. Allerg Immunol (Paris). 2006;38:31–34Ib
  265. Van Metre TE, Adkinson NF, Amodio FJ, et al. A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever. J Allergy Clin Immunol. 1982;69:181–193Ib
  266. Tabar AI, Muro MD, Garcia BE, et al. Dermatophagoides pteronyssinus cluster immunotherapy. A controlled trial of safety and clinical efficacy. J Investig Allergol Clin Immunol. 1999;9:155–164Ib
  267. Nielsen L, Johnsen CR, Mosbech H, Poulsen LK, Malling HJ. Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J Allergy Clin Immunol. 1996;97:1207–1213Ib
  268. Miller DL, Mansmann HC. Rapid injection therapy in children with intractable asthma: safety and technique. Ann Allergy. 1971;29:178–186III
  269. Portnoy J, King K, Kanarek H, Horner S. Incidence of systemic reactions during rush immunotherapy. Ann Allergy. 1992;68:493–498III
  270. Sharkey P, Portnoy J. Rush immunotherapy: experience with a one-day schedule. Ann Allergy Asthma Immunol. 1996;76:175–180III
  271. Hejjaoui A, Dhivert H, Michel FB, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule. J Allergy Clin Immunol. 1990;85:473–479III
  272. Portnoy J, Bagstad K, Kanarek H, Pacheco F, Hall B, Barnes C. Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts. Ann Allergy. 1994;73:409–418Ib
  273. Harvey SM, Laurie S, Hilton K, Khan DA. Safety of rush immunotherapy to multiple aeroallergens in an adult population. Ann Allergy Asthma Immunol. 2004;92:414–419III
  274. Roll A, Hofbauer G, Ballmer-Weber BK, Schmid-Grendelmeier P. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy. J Investig Allergol Clin Immunol. 2006;16:79–85III
  275. Jutel M, Skrbic D, Pichler WJ, Muller UR. Ultra rush bee venom immunotherapy does not reduce cutaneous weal responses to bee venom and codeine phosphate. Clin Exp Allergy. 1995;25:1205–1210III
  276. Bernstein JA, Kagen SL, Bernstein DI, Bernstein IL. Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis. Ann Allergy. 1994;73:423–428III
  277. Kohno Y, Minoguchi K, Oda N, et al. Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma. J Allergy Clin Immunol. 1998;102:927–934IIa
  278. Schiavino D, Nucera E, Pollastrini E, et al. Specific ultrarush desensitization in Hymenoptera venom-allergic patients. Ann Allergy Asthma Immunol. 2004;92:409–413III
  279. Goldberg A, Confino-Cohen R. Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy. Ann Allergy Asthma Immunol. 2003;91:405–410III
  280. Ohashi Y, Nakai Y, Murata K. Effect of pretreatment with fexofenadine on the safety of immunotherapy in patients with allergic rhinitis. Ann Allergy Asthma Immunol. 2006;96:600–605Ib
  281. Muller U, Hari Y, Berchtold E. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J Allergy Clin Immunol. 2001;107:81–86Ib
  282. Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006;117:134–140Ib
  283. Golden DB, Kagey-Sobotka A, Lichtenstein LM. Survey of patients after discontinuing venom immunotherapy. J Allergy Clin Immunol. 2000;105:385–390III
  284. The discontinuation of Hymenoptera venom immunotherapy. J Allergy Clin Immunol. 1998;101:573–575IV
  285. Lerch E, Müller UR. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J Allergy Clin Immunol. 1998;101:606–612III
  286. van Halteren HK, van der Linden PW, Burgers JA, Bartelink AK. Discontinuation of yellow jacket venom immunotherapy: follow-up of 75 patients by means of deliberate sting challenge. J Allergy Clin Immunol. 1997;100:767–770III
  287. Keating MU, Kagey-Sobotka A, Hamilton RG, Yunginger JW. Clinical and immunologic follow-up of patients who stop venom immunotherapy. J Allergy Clin Immunol. 1991;88:339–348III
  288. Golden DB, Kwiterovich KA, Kagey-Sobotka A, Lichtenstein LM. Discontinuing venom immunotherapy: extended observations. J Allergy Clin Immunol. 1998;101:298–302III
  289. Wolf BL, Marks A, Fahrenholz JM. Accidental needle sticks, the Occupational Safety and Health Administration, and the fallacy of public policy. Ann Allergy Asthma Immunol. 2006;97:52–54III
  290. Kanter L. Accidental needle stick prevention: an important, costly, unsafe policy revisited. Ann Allergy Asthma Immunol. 2006;97:7–9IV
  291. Kanter LJ, Siegel C. Needle sticks and adverse outcomes in office-based allergy practices. Ann Allergy Asthma Immunol. 2003;90:389–392III
  292. Position statement on the administration of immunotherapy outside of the prescribing allergist facility. Drugs and Anaphylaxis Committee of the American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 1998;81:101–102
  293. Adkinson NF, Eggleston PA, Eney D, et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med. 1997;336:324–331Ib
  294. Rosenstreich DL, Eggleston P, Kattan M, et al. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. N Engl J Med. 1997;336:1356–1363III
  295. Asero R. Efficacy of injection immunotherapy with ragweed and birch pollen in elderly patients. Int Arch Allergy Immunol. 2004;135:332–335
  296. Theodoropoulos DS, Lockey RF. Allergen immunotherapy: guidelines, update, and recommendations of the World Health Organization. Allergy Asthma Proc. 2000;21:159–166
  297. Litwin A, Flanagan M, Entis G, et al. Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: a double-blind study. J Allergy Clin Immunol. 1997;100:30–38Ib
  298. Bjorksten B, Moller C, Broberger U, et al. Clinical and immunological effects of oral immunotherapy with a standardized birch pollen extract. Allergy. 1986;41:290–295IIa
  299. Oppenheimer J, Areson JG, Nelson HS. Safety and efficacy of oral immunotherapy with standardized cat extract. J Allergy Clin Immunol. 1994;93:61–67Ib
  300. Penagos M, Compalati E, Tarantini F, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol. 2006;97:141–148Ia
  301. Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;118:434–440Ib
  302. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy. 2005;60:4–12Ia
  303. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;117:802–809
  304. Olaguibel JM, Alvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J Investig Allergol Clin Immunol. 2005;15:9–16Ia
  305. Nelson HS, Oppenheimer J, Vatsia GA, Buchmeier A. A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract. J Allergy Clin Immunol. 1993;92:229–236Ib
  306. La Rosa M, Ranno C, Andre C, Carat F, Tosca MA, Canonica GW. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 1999;104:425–432Ib
  307. Passalacqua G, Albano M, Riccio A, et al. Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: a double-blind, placebo-controlled trial. J Allergy Clin Immunol. 1999;104:964–968Ib
  308. Purello-D'Ambrosio F, Gangemi S, Isola S, et al. Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both. Allergy. 1999;54:968–973
  309. Sanchez Palacios A, Schamann F, Garcia JA. [Sublingual immunotherapy with cat epithelial extract. Personal experience]. Allergol Immunopathol (Madr). 2001;29:60–65Ib
  310. Andre C, Perrin-Fayolle M, Grosclaude M, et al. A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship. Int Arch Allergy Immunol. 2003;131:111–118Ib
  311. Khinchi MS, Poulsen LK, Carat F, Andre C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy. 2004;59:45–53Ib
  312. Bernardini R, Campodonico P, Burastero S, et al. Sublingual immunotherapy with a latex extract in paediatric patients: a double-blind, placebo-controlled study. Curr Med Res Opin. 2006;22:1515–1522Ib
  313. Cistero Bahima A, Sastre J, Enrique E, et al. Tolerance and effects on skin reactivity to latex of sublingual rush immunotherapy with a latex extract. J Investig Allergol Clin Immunol. 2004;14:17–25Ib
  314. Marogna M, Spadolini I, Massolo A, et al. Effects of sublingual immunotherapy for multiple or single allergens in polysensitized patients. Ann Allergy Asthma Immunol. 2007;98:274–280
  315. Bagnasco M, Mariani G, Passalacqua G, et al. Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. J Allergy Clin Immunol. 1997;100:122–129IIb
  316. Passalacqua G, Altrinetti V, Mariani G, et al. Pharmacokinetics of radiolabelled Par j 1 administered intranasally to allergic and healthy subjects. Clin Exp Allergy. 2005;35:880–883IIb
  317. Tripodi S, Di Rienzo Businco A, Benincori N, Scala G, Pingitore G. Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children. Int Arch Allergy Immunol. 2006;139:149–152III
  318. Rossi RE, Monasterolo G. A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma. Int J Immunopathol Pharmacol. 2005;18:277–285III
  319. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy. 2006;61:185–190Ib
  320. Kleine-Tebbe J, Ribel M, Herold DA. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy. 2006;61:181–184Ib
  321. Marcucci F, Sensi L, Di Cara G, Incorvaia C, Frati F. Dose dependence of immunological response to sublingual immunotherapy. Allergy. 2005;60:952–956Ib
  322. Cox LS, Linnemann DL, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006;117:1021–1035Ia
  323. Bowen T, Greenbaum J, Charbonneau Y, et al. Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis. Ann Allergy Asthma Immunol. 2004;93:425–430Ib
  324. Agostinis F, Tellarini L, Canonica GW, Falagiani P, Passalacqua G. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. Allergy. 2005;60:133;III
  325. Fiocchi A, Pajno G, La Grutta S, et al. Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann Allergy Asthma Immunol. 2005;95:254–258III
  326. Di Rienzo V, Pagani A, Parmiani S, Passalacqua G, Canonica GW. Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients. Allergy. 1999;54:1110–1113III
  327. Antico A, Pagani M, Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy. 2006;1236–1237
  328. Dunsky EH, Goldstein MF, Dvorin DJ, Belecanech GA. Anaphylaxis to sublingual immunotherapy. Allergy. 2006;61:1235
  329. Eifan AO, Keles S, Bahceciler NN, Barlan IB. Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy. 2007;62:567–568
  330. Georgitis JW, Clayton WF, Wypych JI, Barde SH, Reisman RE. Further evaluation of local intranasal immunotherapy with aqueous and allergoid grass extracts. J Allergy Clin Immunol. 1984;74:694–700IIa
  331. Andri L, Senna G, Andri G, et al. Local nasal immunotherapy for birch allergic rhinitis with extract in powder form. Clin Exp Allergy. 1995;25:1092–1099Ib
  332. Andri L, Senna GE, Betteli C, et al. Local nasal immunotherapy in allergic rhinitis to Parietaria. A double-blind controlled study. Allergy. 1992;47:318–323Ib
  333. Passalacqua G, Albano M, Pronzato C, et al. Long-term follow-up of nasal immunotherapy to Parietaria: clinical and local immunological effects. Clin Exp Allergy. 1997;27:904–908Ib
  334. Passalacqua G, Albano M, Ruffoni S, et al. Nasal immunotherapy to Parietaria: evidence of reduction of local allergic inflammation. Am J Respir Crit Care Med. 1995;152:461–466IIa
  335. Andri L, Senna G, Betteli C, Givanni S, Andri G, Falagiani P. Local nasal immunotherapy for Dermatophagoides-induced rhinitis: efficacy of a powder extract. J Allergy Clin Immunol. 1993;91:987–996Ib
  336. Radcliffe MJ, Lewith GT, Turner RG, Prescott P, Church MK, Holgate ST. Enzyme potentiated desensitisation in treatment of seasonal allergic rhinitis: double blind randomised controlled study. BMJ. 2003;327:251–254Ib
  337. Ippoliti F, De Santis W, Volterrani A, et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol. 2003;14:216–221Ib
  338. Gidaro GB, Marcucci F, Sensi L, Incorvaia C, Frati F, Ciprandi G. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy. 2005;35:565–571III
  339. Smith H, White P, Annila I, Poole J, Andre C, Frew A. Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis. J Allergy Clin Immunol. 2004;114:831–837Ib
  340. Norman PS, Ohman JL, Long AA, et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med. 1996;154:1623–1628Ib
  341. Schramm G, Kahlert H, Suck R, et al. “Allergen engineering”: variants of the timothy grass pollen allergen Phl p 5b with reduced IgE-binding capacity but conserved T cell reactivity. J Immunol. 1999;162:2406–2414LB
  342. Smith AM, Chapman MD, Taketomi EA, Platts-Mills TA, Sung SS. Recombinant allergens for immunotherapy: a Der p 2 variant with reduced IgE reactivity retains T-cell epitopes. J Allergy Clin Immunol. 1998;101:423–425LB
  343. Jain VV, Kitagaki K, Kline JN. CpG DNA and immunotherapy of allergic airway diseases. Clin Exp Allergy. 2003;33:1330–1335LB
  344. Creticos PS, Schroeder JT, Hamilton RG, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med. 2006;355:1445–1455Ib
  345. Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2000;106:253–259Ib
  346. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108:E36;Ib
  347. Milgrom H, Fick RB, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med. 1999;341:1966–1973Ib
  348. Walker S, Monteil M, Phelan K, Lasserson T, Walters E. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev. 2006;CD003559. Ia
  349. Ewan PW, Alexander MM, Snape C, Ind PW, Agrell B, Dreborg S. Effective hyposensitization in allergic rhinitis using a potent partially purified extract of house dust mite. Clin Allergy. 1988;18:501–508
  350. Van Metre TE, Marsh DG, Adkinson NF, Kagey-Sobotka A, Khattignavong A, Norman PS, et al. Immunotherapy for cat asthma. J Allergy Clin Immunol. 1988;82:1055–1068
  351. Van Metre TE, Marsh DG, Adkinson NF, Kagey-Sobotka A, Khattignavong A, Norman PS, et al. Immunotherapy decreases skin sensitivity to cat extract. J Allergy Clin Immunol. 1989;83:888–899
  352. Leynadier F, Banoun L, Dollois B, Terrier P, Epstein M, Guinnepain MT, et al. Immunotherapy with a calcium phosphate-adsorbed five-grass-pollen extract in seasonal rhinoconjunctivitis: a double-blind, placebo-controlled study. Clin Exp Allergy. 2001;31:988–996

 Disclosure of potential conflict of interest: L. Cox has consulting arrangements with Allergy Therapeutics, Genentech/Novartis, and Greer Laboratories and is on the speakers' bureau for Genentech/Novartis, GlaxoSmithKline, and AstraZeneca. R. Lockey has received grant support from Greer Laboratories; served as chairman of an advisory committee for ALK-Abelló for over 7 years; and has served as an expert witness for allergen immunotherapy death for both plaintiff and defendant. H. Nelson has consulting arrangements with Genentech/Novartis, Curalogic, GlaxoSmithKline, Inflazyme Pharmaceuticals, Dey Laboratories, Dynavax Technologies, Altana, and Schering-Plough; has received grant support from Dey Laboratories, IVAX, MediciNova, Wyeth, Sepracor, Genentech, Schering-Plough, Novartis, AstraZeneca, SkyPharma, Altana, and Roche; and is on the speakers' bureau for GlaxoSmithKline and AstraZeneca. D. Bernstein has consulting arrangements with ALK-Abelló and has received grant support from Dynavax and ALK-Abelló. J. Blessing-Moore has received grant support from Novartis-Genentech and AstraZeneca and is on the speakers' bureau for Schering-Plough, Merck, Aventis, Novartis/Genentech, AstraZeneca. D. M. Lang has consulting arrangements with, has received grant support from, and is on the speakers' bureau for GlaxoSmithKline, Merck, AstraZeneca, Centocor, Sanofi-Aventis, Schering-Plough, Verus, and Dey. J. Oppenheimer has consulting arrangements with GlaxoSmithKline, AstraZeneca, Sepracor, and Merck; has received grant support from AstraZeneca, Sepracor, and Merck, Boehringer Ingelheim, Novartis/Genentech, and Schering-Plough; and is on the speakers' bureau for GlaxoSmithKline, AstraZeneca, Sepracor, and Merck. J. M. Portnoy has consulting arrangements with Greer and GlaxoSmithKline; has received grant support from Clorox; and is on the speakers' bureau for Schering-Plough, Merck, Aventis, Secpracor, and AstraZeneca. S. A. Tilles has consulting arrangements with Genentech, Schering-Plough, and GlaxoSmithKline; has received grant support from AstraZeneca, Novartis, Medpoint, Apieron, and ALK-Abelló; and is on the speakers' bureau for GlaxoSmithKline, Pfizer, Genentech, and Alcon. The rest of the authors have declared that they have no conflict of interest.

 Reprint requests: Joint Council of Allergy, Asthma and Immunology, 50 N Brockway St, #3-3, Palatine, IL 60067.

PII: S0091-6749(07)01202-X

doi: 10.1016/j.jaci.2007.06.019

The Journal of Allergy and Clinical Immunology
Volume 120, Issue 3, Supplement , Pages S25-S85 , September 2007

Article Tools

* Image Usage & Resolution